190 related articles for article (PubMed ID: 8102561)
1. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
[TBL] [Abstract][Full Text] [Related]
2. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.
Ross DD; Wooten PJ; Tong Y; Cornblatt B; Levy C; Sridhara R; Lee EJ; Schiffer CA
Blood; 1994 Mar; 83(5):1337-47. PubMed ID: 8118035
[TBL] [Abstract][Full Text] [Related]
3. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
[TBL] [Abstract][Full Text] [Related]
4. Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells.
Hegewisch-Becker S; Faltz C; Hossfeld DK
Eur J Haematol; 1996; 56(1-2):12-22. PubMed ID: 8599988
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
6. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.
Nooter K; Sonneveld P; Oostrum R; Herweijer H; Hagenbeek T; Valerio D
Int J Cancer; 1990 Feb; 45(2):263-8. PubMed ID: 1968051
[TBL] [Abstract][Full Text] [Related]
8. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
Leuk Res; 2003 Feb; 27(2):183-91. PubMed ID: 12526924
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies.
Van Acker KL; Van Hove LM; Boogaerts MA
Cytometry; 1993 Oct; 14(7):736-46. PubMed ID: 7902231
[TBL] [Abstract][Full Text] [Related]
10. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
[TBL] [Abstract][Full Text] [Related]
11. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
[TBL] [Abstract][Full Text] [Related]
12. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric assessment of multidrug resistance (MDR) phenotype in acute myeloid leukaemia.
Hart SM; Ganeshaguru K; Lyttelton MP; Prentice HG; Hoffbrand AV; Mehta AB
Leuk Lymphoma; 1993 Oct; 11(3-4):239-48. PubMed ID: 7903178
[TBL] [Abstract][Full Text] [Related]
14. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.
Broxterman HJ; Sonneveld P; Feller N; Ossenkoppele GJ; Währer DC; Eekman CA; Schoester M; Lankelma J; Pinedo HM; Löwenberg B; Schuurhuis GJ
Blood; 1996 Jun; 87(11):4809-16. PubMed ID: 8639853
[TBL] [Abstract][Full Text] [Related]
15. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression.
Marie JP; Faussat-Suberville AM; Zhou D; Zittoun R
Leukemia; 1993 Jun; 7(6):825-31. PubMed ID: 8099135
[TBL] [Abstract][Full Text] [Related]
16. Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia.
Ross DD; Joneckis CC; Schiffer CA
Blood; 1986 Jul; 68(1):83-8. PubMed ID: 3719105
[TBL] [Abstract][Full Text] [Related]
17. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
18. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
19. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
Broxterman HJ; Sonneveld P; Pieters R; Lankelma J; Eekman CA; Loonen AH; Schoester M; Ossenkoppele GJ; Löwenberg B; Pinedo HM; Schuurhuis GJ
Leukemia; 1999 Feb; 13(2):258-65. PubMed ID: 10025900
[TBL] [Abstract][Full Text] [Related]
20. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Berman E; McBride M
Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
